| Identification | Back Directory | [Name]
S(-)-RACLOPRIDE L-TARTRATE | [CAS]
84225-95-6 | [Synonyms]
RAC
FLA-870
RACLOPRIDE
Racloprida
Raclopridum
Raclopridum [latin]
Racloprida [spanish]
S(-)-RACLOPRIDE L-TARTRATE
-2-hydroxy-6-methoxybenzamide
-3,5-Dichloro-N-((1-ethylpyrrolidin-2-yl)
3,5-Dichloro-N-[(2S)-1-ethyl-2-pyrrolidinyl]-2-hydroxy-6-methoxybenzamide
(-)-(S)-3,5-Dichlor-N-((1-ethyl-2-pyrrolidinyl)methyl)-6-hydroxy-o-anisamid
(2S)-3,5-DICHLORO-N-[(1-ETHYL-2-PYRROLIDINYL)-METHYL]-6- METHOXYSALICYLAMIDE
(S)-3,5-Dichloro-N-((1-ethylpyrrolidin-2-yl)Methyl)-2-hydroxy-6-MethoxybenzaMide
3,5-Dichloro-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2-methoxy-6-hydroxybenzamide
3,5-DICHLORO-N-[[(2S)-1-ETHYL-2-PYRROLIDINYL]METHYL]-2-HYDROXY-6-METHOXYBENZAMIDE
(2S)-3,5-DICHLORO-N-[(1-ETHYL-2-PYRROLIDINYL)METHYL]- 6-HYDROXY-2-METHOXYBENZAMIDE
3,5-Dichloro-N-[[(2S)-1-ethylpyrrolidine-2α-yl]methyl]2-hydroxy-6-methoxybenzamide
BENZAMIDE, 3,5-DICHLORO-N-[[(2S)-1-ETHYL-2-PYRROLIDINYL]METHYL]-2-HYDROXY-6-METHOXY-
Benzamide, 3,5-dichloro-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-hydroxy-6-methoxy-, (-)- | [Molecular Formula]
C19H26Cl2N2O9 | [MDL Number]
MFCD00274072 | [MOL File]
84225-95-6.mol | [Molecular Weight]
497.32 |
| Chemical Properties | Back Directory | [Appearance]
Yellowish solid | [Melting point ]
52.0 to 56.0 °C | [Boiling point ]
420.3±45.0 °C(Predicted) | [density ]
1.288±0.06 g/cm3(Predicted) | [storage temp. ]
Store at RT | [solubility ]
H2O: 89 mg/mL
| [form ]
solid
| [pka]
5.93±0.50(Predicted) | [color ]
white
|
| Hazard Information | Back Directory | [Chemical Properties]
Yellowish solid | [Uses]
A labelled dopamine receptor | [Uses]
neuroleptic;selective dopamine D1/D2 receptors antagonist | [Biological Activity]
Selective and potent dopamine D 2 /D 3 receptor antagonist (K i values are 1.8, 3.5, 2400 and 18000 nM for D 2 , D 3 , D 4 and D 1 receptors respectively). Centrally active following systemic administration in vivo . | [Description]
Raclopride is a selective dopamine D2/D3 receptor antagonist with Ki values of 1.8, 3.5, 2,400, and 18,000 nM for D2, D3, D4, and D1 receptors, respectively.1 It passes the blood brain barrier and can be used in in vivo binding and autoradiography studies of the dopamine system under normal and pathological conditions such as Huntington’s disease.2,3 | [Definition]
ChEBI: 3,5-dichloro-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-6-methoxybenzamide is a member of salicylamides. | [storage]
Store at -20°C |
|
|